The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. It is
an area of active research. This article is aimed to give an update on recent advances in all …

Fibrosis is a pivotal player in heart failure development and progression. Measurements of
(markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with …

The co‐occurrence of cancer and heart failure (HF) represents a significant clinical
drawback as each disease interferes with the treatment of the other. In addition to shared …

Emerging evidence supports that cancer incidence is increased in patients with
cardiovascular (CV) disease and heart failure (HF), and patients with HF frequently die from …

Research about heart failure (HF) has made major progress in the last years. We give here
an update on the most recent findings. Landmark trials have established new treatments for …

Advances in cancer treatments have improved clinical outcomes, leading to an increasing
population of cancer survivors. However, this success is associated with high rates of short …

Aims Cardio‐oncology clinics optimise the cardiovascular status of cancer patients but there
is a limited description of their structure, case mix, activity and results. The purpose of this …

In western countries, cardiovascular (CV) disease and cancer are the leading causes of
death in the ageing population. Recent epidemiological data suggest that cancer is more …

Aims Better management of heart failure (HF) over the past two decades has improved
survival, mainly by reducing the incidence of death due to cardiovascular (CV) causes …